Navigation Links
New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
Date:10/15/2007

PHILADELPHIA, Oct. 15 /PRNewswire-FirstCall/ -- Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) ulcerative colitis (UC) drug LIALDA(TM) (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis. These analyses of LIALDA's 303 trial, a long-term, Phase III, open-label 12-14 month extension study, are being presented this week at The American College of Gastroenterology (ACG) meeting in Philadelphia.

The primary endpoint of study 303 was safety and tolerability and findings -- that LIALDA is generally well tolerated in mild to moderate UC patients -- were presented at the British Society of Gastroenterology (BSG) meeting in Glasgow, Scotland in March 2007.

"Earlier studies showed that LIALDA is well-tolerated and effective at inducing remission in patients with active, mild to moderate UC. Post-hoc analysis of secondary endpoints provided evidence that LIALDA maintained remission in a variety of UC patients," said Gary R. Lichtenstein, M.D., director of the Center for Inflammatory Bowel Diseases at the Hospital of the University of Pennsylvania.

A summary of key scientific presentations of post-hoc analyses of secondary endpoints of study 303 follows.

Once or Twice Daily LIALDA for Mild vs. Moderate Ulcerative Colitis

Poster Presentation: Tuesday, October 16, 2007, Exhibit Hall B, #950

A post-hoc analysis of secondary endpoints from the long-term 303 study was performed to review the efficacy of LIALDA for maintaining remission in patients with mild versus moderate ulcerative colitis. In the 303 study, patients were randomized to receive LIALDA 2.4g/day (given once daily [QD]) or 2.4g/day (1.2g given twice daily [BID]). Study 303 defined patient remission using stringent clinical and endoscopic measures: modified UC Disease Activity Index (UC-DAI) score of less than or equal to 1 with score
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
10. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
11. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  ResMed Inc. (NYSE: RMD ) today announced ... for the quarter was $453.1 million, a 9 percent ... (a 17 percent increase on a constant currency basis). ... ended June 30, 2014.  Diluted earnings per share for ... June 30, 2014.  The results for ...
(Date:7/30/2015)... bring you a special edition of #MedicareMonday on Medicare,s 50 th anniversary. As ... resources and continue highlighting the success of the prescription drug benefit, commonly referred to ... our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... OAKS, Calif., July 30, 2015  Amgen (NASDAQ: ... the second quarter of 2015. Key results include: ... the second quarter of 2014 to $5,370 million, ... by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable changes ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19
... and FARGO, N.D., Dec. 16, 2011  Crystal3 Labs, Inc., a ... FL, announced today that it has been acquired by ... Financial terms of the transaction were not disclosed. The ... Pharma Analytics. Founded in 2007, Global Pharma ...
... 2011 Ekahau Inc. the leading global provider ... and KARL STORZ GmbH & Co. KG, the endoscopy specialist, ... Clinic in Berlin has successfully deployed and is using the ... and Ekahau RTLS for automatic real-time management of ...
Cached Medicine Technology:Crystal3 Labs Acquired by Individual Investor, Vithalbhai Dhaduk, M.D. 2Hospital Operating Rooms are now Optimized in Real-time With a Joint Solution From Karl Storz and Ekahau 2Hospital Operating Rooms are now Optimized in Real-time With a Joint Solution From Karl Storz and Ekahau 3Hospital Operating Rooms are now Optimized in Real-time With a Joint Solution From Karl Storz and Ekahau 4
(Date:7/30/2015)... ... 2015 , ... When responsible for the care of an aging loved one, ... your mind: What happens if mom falls? Who will remind Dad to take his ... , But not taking time away from caregiving responsibilities can lead to bigger problems ...
(Date:7/30/2015)... ... July 31, 2015 , ... Committed to helping the next generation succeed - ... to contribute to the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues ... track. Providing the support they need to think more broadly about their future. Building ...
(Date:7/30/2015)... , ... July 30, 2015 , ... In an effort ... hospitalized, Dr. Aggarwal is making a change in his practice. , The decision will ... August 14, 2015, Dr. Aggarwal will be transferring his in-patient admissions to the hospitalists ...
(Date:7/30/2015)... ... 30, 2015 , ... Eyepartner is proud to highlight that ... California’s Gaslamp Quarter Plaza for five years this September. , The surveillance ... for any suspicious activity. These cameras are in place to provide inarguable proof ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Report, which takes a look at small, medium, and large businesses making an ... expert, conducted the business review and shared with viewers how DevExpress has provided ...
Breaking Medicine News(10 mins):Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, Nov. 16 ... path to becoming obese adults at higher risk of type 2 ... study finds. But if they manage to get their weight ... higher risk of those health problems than people who were normal ...
... medicine physician and medical student members of the American ... urging the Joint Select Committee on Deficit Reduction to ... INNOVATION ACT. This proposal repeals the flawed Medicare ... systems for physicians providing services to patients enrolled in ...
... DeLuca, PhD, Vice President for Research at Kessler Foundation ... for cognitive rehabilitation in people with multiple sclerosis (MS). ... the Neuropsychology & Neuroscience Laboratory at Kessler Foundation. ... on October 21, 2011 in Amsterdam at the 5th ...
... Orthopaedic Surgeons (AAOS) Board of Directors has recently approved ... "The Treatment of Supracondylar Humerus Fractures." ... the Trauma Program at the University of Toronto Hospital ... Work Group responsible for this CPG, said that surgeons ...
... testing of the first practical "smart" material that may supply ... form of light that can penetrate four inches into the ... material, which has potential for use in diagnosing diseases and ... journal Macromolecules . Adah Almutairi and colleagues explain ...
... The bacteria Enterococcus can cause infections that typically ... an abdominal abscess or urinary infection could result. Enterococcus ... or endocarditis an infection of the heart valve. Typically ... the elderly and those who already have health issues, such ...
Cached Medicine News:Health News:Outlook Good for Obese Kids Who Lose Weight 2Health News:Outlook Good for Obese Kids Who Lose Weight 3Health News:Internists 'applaud' Schwartz Proposal to prevent 'devastating' Medicare cuts 2Health News:AAOS issues new clinical practice guideline for treating common elbow fractures in children 2Health News:Wayne State University to study novel treatment for antibiotic-resistant bacteria 2
... Hoefers Easy Breeze can dry as many as 6 ... (8 x 10 cm) at a time. , ... oven, a specially designed loading platform, and two Hoefer ... awkward connections., The Gel Frame is largely responsible for ...
... dry gels rapidly, evenly and safely, the Hoefer ... and vacuum are applied beneath the gel through ... and agarose gels up to 33 x 44 ... heavy aluminum platen provides even heat distribution and ...
... system, 220-240 V, includes Model 583 gel dryer, ... gel dryer is a vacuum-based gel dryer with ... with variable temperature control and three preprogrammed cycles. ... pump used for pulling vacuum on gel dryers ...
This double-up gel dryer system, 200-240 V, includes 2 Model 583 gel dryers, HydroTech™ vacuum pump, and double-up rack....
Medicine Products: